We advise you to avoid simply saving the image previews you see below. These wallpaper previews are compressed and optimized for improved website performance. Instead, you should click the button ...

SAR-446422 is under clinical development by Sanofi and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) ...

Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for t ...

The use of Sanofi’s Dupixent in atopic dermatitis has set a high benchmark for competitors within the space. Credit: marishkaSm via Shutterstock. Sanofi’s participation at the JP Morgan 43rd Annual ...

Having slept at the Big Brother house three times, I can say that this year’s visit made me truly experience how being a housemate really is. From vibes, to games, drama, shock and surprises, we ...

Microsoft has recently introduced a new collection of desktop wallpapers to its website, offering a wide variety of wallpapers for download. The latest collection, ‘Fluid Textures,’ was designed by 3D ...

Sanofi’s Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 ...

Visit leroymerlin.co.za. Featuring a charming assortment of British ducks, Mulberry Home’s Duck Pond design from the Country Walk wallpaper collection captures the serene beauty of an ornamental pond ...

Wallpaper’s Ellie Stathaki delves into what defined the 2025 Wallpaper* Architecture Awards Wellbeing and restorative strategies are increasingly coming to the forefront of our efforts to nurture ...

Design Awards 2025: Alvar Aalto's Finlandia Hall is a modernist gem reborn through sustainability and accessibility Helsinki's Finlandia Hall, an Alvar Aalto landmark design, has been reborn - ...

Snapshot of the implementation used to generate figures and numerical results from the paper "Sharp Bounds for Continuous-Valued Treatment Effects with Unobserved ...

Sanofi has tapped Alloy Therapeutics to enable development of a central nervous system drug, agreeing to pay $27.5 million in upfront and near-term fees to access an antisense platform. Alloy is ...